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PATENT ARBITRATION: THE UNDERUTILIZED PROCESS FOR RESOLVING INTERNATIONAL 
PATENT DISPUTES IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES 
By 
Alessandra Emini* 
I. INTRODUCTION 
“The theoretical advantages of arbitration over court adjudication are manifold. . . . These 
theoretical advantages [however] are not always fully realized.” – Frank Sander1 
 
 International patent arbitration is an underutilized method of dispute resolution that 
has the potential to yield many benefits for companies within the pharmaceutical and 
biotechnology industries.  These industries would benefit from international patent 
arbitration because patents are the companies’ primary assets, the costs of research and 
development (“R&D”) are high, and limited patent monopolies create a tight time 
constraint for receiving a return on costs.  Additionally, the positive impact the 
biotechnology and pharmaceutical industries have on universal health puts pressure on the 
companies’ need for a quick, efficient, and low cost international resolution process.  
Arbitration provides just that.  Arbitration is a blank canvas on which the parties have 
complete autonomy to modify the procedures to best fit their needs.  This autonomy places 
a substantial amount of beneficial power in the hands of the companies and significantly 
diminishes the constraints of international litigation.  The beneficial impact international 
arbitration has had for companies led it to become the standard method of dispute 
resolution among the energy, construction, insurance, shipping and commodities 
industries.  Furthermore, this trend has extended to countries as a whole with many 
countries openly endorsing international arbitration.  In particular, the United States 
Supreme Court has explicitly recognized “an emphatic federal policy in favor of arbitral 
dispute resolution.”2  Once the biotechnology and pharmaceutical industries embrace the 
use of patent arbitration, they will experience benefits that simply cannot be achieved in 
litigation. 
                                                 
*Alessandra Emini is an Associate Editor of the Yearbook on Arbitration and Mediation and a 2019 Juris 
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1 Peter L. Michaelson, Patent Arbitration: It Still Makes Good Sense, 7 LANDSLIDE (JOURNAL OF THE ABA 
SECTION OF INTELLECTUAL PROPERTY), (July 23, 2015), 1, 8, 
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2635036 (quoting CIArb Costs of International 
Arbitration Survey 2011, CHARTERED INST. OF ARBITRATORS (CIARB), at ii (2011)). 
 
2 Marmet Health Care Ctr., Inc. v. Brown, 132 S. Ct. 1201, 1203 (2012). 
A. Background 
 At their core, patents are the life-blood of the pharmaceutical and biotechnology 
industries.3  Patents create property rights in the physical and intangible inventions of 
artistic persons.4  A patent, however, does not provide an international right of ownership 
of the invention to the patentee.5  A patent is only enforced within the jurisdictions in which 
the patentee applied for the patent and within the sovereign states that granted it.6  For an 
invention to be patentable, it must be a “new and useful process, machine, manufacture, or 
composition of matter, or any new and useful improvement thereof.”7   The global-standard 
life of a patent is twenty years from the date of filing.8  Once granted, the patent holder has 
the exclusive right to choose who “makes, uses, offers to sell, or sells” the patented 
invention.9  However, the way in which a patent holder exercises this exclusive right varies 
by the industry.10  Some industries, such as the electronic industry, require a method of 
patent sharing and cross licensing because many new products contain previously patented 
technologies.11  Alternatively, industries such as the pharmaceutical and biotechnology 
sectors use patents as equivalents to market products.12  By equating patents to market 
products, these industries have to invest large sums of money in research, development, 
and clinical testing before placing their patented products into the marketplace.13  The high 
cost of R&D,14 the ease of reverse engineering pharmaceutical and biotechnology 
                                                 
3 Henry G. Grabowski & John M. Vernon, Effective Patent Life in Pharmaceuticals, 19 INT. J. TECH. MGMT., 
98 (2000); see also Esteban Burrone, Patents at the Core: the Biotech Business, WORLD INTELLECTUAL 
PROPERTY ORGANIZATION, http://www.wipo.int/sme/en/documents/patents_biotech_fulltext.html. 
 
4 Bruce Lehman, The Pharmaceutical Industry and the Patent System, INTERNATIONAL INTELLECTUAL 
PROPERTY INSTITUTE, 1 (2003). 
5 Id. at 4. 
6 Id. 
7 35 U.S.C. § 101 (2012). 
8 Lehman, supra note 4, at 4. 
9 35 U.S.C. § 271(a) (2012). 
10 Lehman, supra note 4, at 2. 
11 Id. 
12 Id. 
13 Id. 
14 Id. 
products,15 and the impact these products have on universal health16 highlight the 
indispensable need for and significant role of patents in the pharmaceutical and 
biotechnology industries. 
 The pharmaceutical and biotechnology industries rank among the top industries 
requiring patents to procure returns on R&D of new inventions and future products.17  In 
the biotechnology industry alone, patents granted by the United States Patent and 
Trademark Office increased 15% per year and those granted at the European Patent Office 
increased 10.5% per year from 1990-2000.18  These percentages are a stark contrast to the 
mere 5% annual increase in patents granted overall.19  The percentages reflect the fact that 
these industries rely heavily on intellectual property (“IP”) and invest nearly half of all 
revenues in R&D.20  To illustrate, development and market approval can last longer than a 
decade and cost approximately $2.6 billion on average.21  This cost rises to approximately 
$2.9 billion in post-approval R&D.22  However, the return on the cost for R&D is reduced 
because nearly half of the patent term has passed before the drug or technology enters the 
market.  This effectively cuts the patent life from 20 years to an average of 11.5 years.23  
The shortened exclusivity period is unique to these industries because unlike the computer 
and software industries, which can keep new inventions secret until their entrance into the 
market, medical research is highly regulated and scientists are obligated to share findings 
for the benefit of their peers.24    
 Alongside the repayment of R&D, the imitation of new inventions is an area of 
large concern for these industries.25  According to the founders of Nordic Biotech, “the 
present reality in drug development . . . is that almost any technology or compound can 
                                                 
15 Burrone, supra note 3. 
16 2015 Biopharmaceutical Research Industry Profile, PHARMACEUTICAL RES. AND MFR. OF AM., Apr. 2015. 
17 Grabowski & Vernon, supra note 3, at 98 (referencing the study by R.D. Levin et al., Appropriating The 
Returns from Industrial Research and Development, BROOKINGS PAPERS ON ECON. ACTIVITY, 783 (1987)). 
 
18 Org. for Econ. Co-Operation and Dev., GENETIC INVENTIONS, INTELLECTUAL PROPERTY RIGHTS AND 
LICENSING PRACTICES, 1, 8 (2002), https://www.oecd.org/sti/sci-tech/2491084.pdf. 
 
19 Id. 
 
20 Burrone, supra note 3. 
 
21 Joseph A. DiMasi, Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs, TUFT CENTER 
FOR THE STUDY OF DRUG DEVELOPMENT (Nov. 18, 2014), 
http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study (note that these figures are 
expressed in 2013 dollars). 
 
22 Id. 
 
23 Harsha Rohatgi, The Importance of Patents in the Pharmaceutical Industry, EYESPAT (Feb. 2014), 
http://www.eyespat.com/the-importance-of-patents-in-pharmaceutical-industry/. 
 
24 Lehman, supra note 4, at 7. 
25 Id. 
 
rapidly be reverse engineered.”26  The products themselves often do not require “expensive 
and complex manufacturing infrastructures” and can therefore “be easily and cheaply 
replicated by copiers with little capital investment.”27  The majority of capital investment 
is disproportionately placed into R&D and not into manufacturing. Thus, the exclusivity 
procured through patents is the only way for companies within these industries “to protect 
and receive a return” on their investments.28  Furthermore, only 12% of all drugs that enter 
clinical trials are approved.29  The low rate of marketplace success illustrates the necessity 
of patent protection for those drugs that are eventually released to the public.  Without the 
incentive of patents to provide return on investments and prevent competitor product 
duplication, these industries would not create the life-saving products they are delivering 
today.30 
 The impact the pharmaceutical and biotechnology industries have had on universal 
health is monumental.  Since the peak of cancer death rates in the 1990s, there has been a 
decline of nearly 22%, with 83% of survival gains owed to new treatments and medicines.31  
Since 1995 and the introduction of highly active antiretroviral treatment (HAART), the 
HIV/AIDS death rate has decreased by nearly 85% and approximately 862,000 premature 
deaths were averted in the United States alone.32  In 2014, for example, two drugs were 
approved to treat advanced melanoma, two antiviral combination therapies were approved 
to treat hepatitis C with “a cure rate of more than 90% in as few as eight weeks”, and four 
new antibiotics were approved to treat serious infections.33  Therefore, because of the 
positive impact these industries have on universal health, the high costs of R&D, and the 
tight time constraint of their limited monopoly provided by patents,34 pharmaceutical and 
biotechnology companies need to resolve patent disputes quickly, efficiently and at a low 
cost.  This form of resolution can be achieved through international arbitration. 
                                                 
26 Florian Schonharting & Christian Hansen, Intellectual Property and Investment in Biotech, in MEDICON 
VALLEY PATENT GUIDE, 1, 24 (2002), 
http://www.cbs.dtu.dk/courses/27614/material/patents/Medicon_Valley_Patent_Guide.pdf. 
 
27 Lehman, supra note 4, at 7. 
28 Id. 
29 Profile, supra note 16, at 2. 
30 Id. at 8. 
31 Id. at 2. 
32 Id. 
33 Id. at 11-12. 
34 Ronald E. Dimock & Michael Rubinger, 7 Benefits of Arbitration In A Patent Dispute, LAW360 (Aug. 27, 
2015), https://www.law360.com/articles/695649/7-benefits-of-arbitration-in-a-patent-dispute. 
 Historically, companies facing patent disputes have lagged behind in utilizing 
international arbitration as a tool for dispute resolution.35  International arbitration has 
become a primary mechanism for companies resolving commercial disputes.36  According 
to the PwC 2013 International Arbitration Survey, 52% of corporate respondents chose 
arbitration as their most preferred dispute resolution tactic, followed by court litigation 
with 28% of the vote.37  By industry, 56% of respondents in the Energy sector and 68% of 
respondents in the Construction sector preferred arbitration to other methods of 
resolution.38  This trend has also conveyed itself in countries as a whole with the United 
States being at the forefront of alternative dispute resolution having recognized “an 
emphatic federal policy in favor of arbitral dispute resolution.”39  However, despite this 
trend, international patent disputes are rarely submitted to arbitration and are usually settled 
via litigation where jurisdiction is limited and the enforcement of awards is not guaranteed 
internationally.40  This runs contrary to the increasing global impact of patents and the 
international push towards a unified patent system.41  When applied appropriately, the use 
of patent arbitration for companies in the pharmaceutical and biotechnology industries not 
only helps resolve international disputes in a nearly unified method, but it also provides 
confidentiality while saving significant time and costs.42 
II. THE INEFFICIENCIES OF LITIGATION 
 Patents are among the most important assets companies have within the 
pharmaceutical and biotechnology industries.43  Patent protection is essential for these 
companies to ensure they remain competitive in the market and license their inventions to 
                                                 
35 Felicia J. Boyd, .A Way To Efficiently Resolve International Patent Disputes, LAW360 (Feb. 8, 2016), 
https://www.law360.com/articles/743379/a-way-to-efficiently-resolve-international-patent-disputes. 
36 Id.; see also Forward: Guide to International Arbitration, LATHAM & WATKINS, 1 (2015), 
https://www.lw.com/thoughtleadership/guide-to-international-arbitration-2014 (“In modern times, 
arbitration became the standard method for resolving disputes in certain industry sectors (such as 
construction, commodities, shipping and insurance) where the arbitrators’ technical expertise was 
particularly valued.”). 
37 Corporate Choices in International Arbitration, PWC, 1, 6 (2013), 
https://www.pwc.com/gx/en/arbitration-dispute-resolution/assets/pwc-international-arbitration-study.pdf.  
38 Id. at 7. 
39 Marmet, 132 S. Ct. at 1203. 
40 Boyd, supra note 35. 
41 See Patent Cooperation Treaty, June 19, 1970, 28 U.S.T. 7645, 1160 U.N.T.S. 231. 
42 Michaelson, supra note 1, at 3. 
 
43 David A. Allgeyer, In Search of Lower Cost Resolution: Using Arbitration to Resolve Patent Disputes, 12 
CONFLICT MGMT. NEWSL. OF THE SEC. OF LITIG.’S COMMITTEE ON ALTERNATIVE DISP. RESOL. 1, 9 (2007). 
 
others.44  However, the value of patents places companies within these industries at a 
significant risk of entering litigation over patent disputes.45  Between 2010 and 2012, in 
the top ten countries for patent suits – China, the U.S., Germany, France, Italy, Japan, India, 
Taiwan, England, and Canada – there were approximately 70,400 cases.46  In the U.S., 
patent suits increased 120% since 2004.47  Likewise, China had 9,680 suits filed in 2012, 
nearly 80% greater than the total number of suits filed in the U.S. that same year.48  Yet, 
despite the trend of increasing patent litigation world-wide, the benefits of the litigation 
system are greatly outweighed by its inefficiencies.49  This includes the length of time 
required to litigate a patent dispute, the high costs of discovery and motions, the 
unspecialized court systems that often include judges without technical backgrounds, and 
the public forum. 
A. Extensive Length of Time to Litigate a Patent Dispute 
 The length of time to litigate a patent dispute is one of litigation’s principal 
drawbacks.  Parties of a patent dispute may only litigate the issue within a court and country 
that has jurisdiction.50  To illustrate, in the U.S., time-to-trial averages two and a half 
years,51 and litigation can continue for as long as twenty-five years.52  For example, the 
longest lasting patent infringement case, Hughes Aircraft Co. v. United States, was filed in 
1973 and remained unresolved until 1998, twenty-five years later.53  Notably, time-to-trial 
has increased dramatically in the last twenty years in proportion to the rise of patent cases 
filed annually.54  Once the parties have waited for litigation to commence, additional time 
                                                 
44 Allgeyer, supra note 43, at 9. 
 
45Id.; See also CRISPR UPDATE, http://www.crisprupdate.com/category/crispr-patents/  (offering a present 
day example of a hard fought litigation patent dispute across two continents over the Crispr/Cas9 invention). 
 
46 Significant Trends in Global Patent Litigation, GLOBAL IP PROJECT, LLC, 2 (2015), 
http://globalpatentmetrics.com/wp-content/uploads/2015/01/Significant-Trends-Slides-25-Jan-2015.pdf. 
 
47 Id. at 10. 
 
48 Brian Love, Christine Helmers, and Markus Eberhardt, Patent Litigation in China: Protecting Rights or 
the Local Economy? (2016), http://digitalcommons.law.scu.edu/facpubs/918. 
49 Michaelson, supra note 1, at 3 
 
50 Lehman, supra note 4, at 4 
51 Chris Barry et al., Are We At An Inflection Point?, 2016 PATENT LITIGATION STUDY (May 2016), 
https://www.pwc.com/us/en/forensic-services/publications/assets/2016-pwc-patent-litigation-study.pdf. 
 
52 See e.g. Hughes Aircraft Co. v. United States, 140 F.3d. 1470 (Fed. Cir. 1998). 
 
53 Id. 
54 Barry, supra note 51, at 3. 
 
is spent following the country’s expansive rules of procedure.55  These rules include 
exhaustive discovery, depositions, and potentially futile motions56 resulting in patent 
litigation that averages 23.4 months.57  The time to complete a patent suit is potentially 
lengthened by a “Markman” hearing as well.58  Markman hearings, also referred to as 
“claim construction hearings,” are pre-litigation hearings “in which a judge determines the 
meaning of words from the patent claims that are in dispute in a patent infringement 
lawsuit.”59  Even after the final decision is rendered in litigation, parties can appeal the 
court’s result.  In 2015, 80% of the decisions made on patent disputes in U.S. District 
Courts were appealed.60  On average, an appeal adds an extra 30.8 months to the litigation 
process.61  Of those disputes appealed, 53% resulted in some type of a modification of the 
lower court ruling.62  Therefore, the average patent litigation in the U.S., from filing a claim 
to a decision rendered after an appeal, can last more than half a decade.   
 The U.S. is not the only country that has a lengthy patent litigation system.  Courts 
in France, where approximately 350 patent cases are filed annually, take an average of 15 
to 24 months to render a decision in the tribunal de grande instance.63  If the decision is 
appealed, the cour d’appel takes an average of 24 months to render a judgment and, if the 
decision is brought to the Cour de cassation, the parties wait an additional 18 to 24 months 
for that court to render a final decision.64  Courts in Korea faced with a first instance 
infringement lawsuit can take as little as 9 to 18 months to render a decision.65  From filing 
to rendering a decision, however, an expedited review of a civil court invalidation action 
with a parallel infringement action lasts 2.5 to 4 years in civil court and 2 to 3.5 years in 
                                                 
55 Michaelson, supra note 1, at 3. 
 
56 Id. at 5. 
 
57 Dimock, supra note 34. 
58 Allgeyer, supra note 43, at 9. 
 
59 MARKMAN HEARING, http://www.markmanhearing.org. 
60 Barry, supra note 51, at 2. 
61 Dimock, supra note 34. 
62 Barry, supra note 51, at 2. 
 
63 Global IP Project, supra note 46, at 23.  The tribunal de grande instance is the court which hears first 
instance disputes which would not otherwise be attributed to a different court and play a similar role to the 
District Courts in the United States. 
64 Id.  The cour d’appel is the appeals court that reviews decisions rendered in the tribunal de grande instance.  
The Cour de cassation is the court of last resort and is similar to that of the Supreme Court in the United 
States. 
65 Id. at 36. 
KIPO, Korea’s IP tribunal.66  In spite of each country’s average patent litigation time, 
national courts in international litigation have delays that can easily exceed five to ten 
years.67  Ultimately, the patent litigation system results in a significant amount of lost time, 
with IP remaining in patent legal limbo until the dispute is resolved.68 
B. The High Costs of Litigating an International Patent Dispute 
 The costs to litigate a patent dispute are increased by exhaustive discovery, the 
necessity of witness testimony, pretrial depositions, and disputes regarding the discovery 
process.69  A 2015 study conducted by the American Intellectual Property Law Association 
(“AIPLA”) found that the average cost for litigation in a U.S. patent infringement case for 
a claim over $25 million was $6.3 million, with the costs of discovery averaging about $3.7 
million.70  Alongside the U.S., the United Kingdom is also considered a high-cost country 
for patent litigation.71  For example, Research in Motion spent £6 million ($9.1 million) in 
its litigation case against Visto and Johnson & Johnson spent £3.7 million ($5.7 million) 
in its contact lens case against CIBA.72  International enforcement of patents, however, 
typically involves multiple parallel judicial proceedings of similar patent claims in various 
national courts.73  Thus, companies are forced to enforce their patents before multiple 
courts across several continents and within a multitude of different countries.  The 
European Commission issued a February 2009 report that estimated party costs for large 
commercial cases in France, Germany, the Netherlands, and the U.K.74  These costs amount 
to €200,000 ($266,000) in France and the Netherlands, €250,000 ($332,000) in Germany, 
and €1.5 million ($2 million) in the U.K.75  The excessive costs of patent litigation leave 
                                                 
66 Global IP Project, supra note 46, at 39. 
67 Michaelson, supra note 1, at 6. 
 
68 Allgeyer, supra note 43, at 9. 
 
69 Id. 
 
70 AIPLA 2015 Report of the Economic Survey, INTELL. PROP. INS. CORP. (2015), 
http://www.patentinsuranceonline.com/wp-content/uploads/2016/02/AIPLA-2015-Report-of-the-
Economic-Survey.pdf (compiling the average costs of litigation found within the 2015 Report of the 
Economic Survey released by the American Intellectual Property Law Association). 
 
71 World Intell. Prop. Org. (WIPO), IP Litigation Costs, WIPO MAGAZINE, Feb. 2010, at 1, 6, 
http://www.wipo.int/export/sites/www/wipo_magazine/en/pdf/2010/wipo_pub_121_2010_01.pdf. 
72 Id. at 8 (using the 2010 conversion rate between the pound and the U.S. dollar used to express equivalency). 
73 Id. at 12. 
 
74 Id. 
75 Id. (using the 2009 conversion rate between the euro and the U.S. dollar used to express equivalency). 
small and medium-sized enterprises unable to enforce their international patent rights76 and 
many alleged infringers settle to avoid legal expenses even if they were likely to succeed 
in their defense in court.77   
C. Court Systems and Judicial Knowledge on the Subject Matter 
 Internationally, each country’s patent litigation system and requirements for 
specialized judges with technical backgrounds are different.78  Studies suggest that 
specialized patent courts with technically trained judges have a lower patent claim reversal 
rate.79  Donna M. Gitter conducted a study comparing the reversal rate of U.K. specialist 
patent judges, all with technical experience, to the reversal rate of U.S. District Court 
judges.80  Gitter concluded that the reversal rate of U.S. District Courts outnumbered that 
of the specialized U.K. patent courts, suggesting that specialized patent courts have a lower 
reversal rate.81  This is a strong indicator that judicial knowledge on the subject matter 
saves time and costs. 
 Of the top ten countries in patent litigation, only two countries – Taiwan and the 
U.K. – have specialized IP courts, and Canada is the only country with a trial court that 
hears only IP cases.82  However, five countries – China, Japan, France, Germany, and Italy 
– have a specialized IP division in their court systems.83  Yet the U.S., the country with the 
second largest number of patent cases heard, and India, the seventh leading country in 
patent disputes, have no specialized IP court system at all.84  The international 
                                                 
76 WIPO, supra note 71, at 12. 
77 Michaelson, supra note 1, at 1. 
 
78 Rohazar Wati Zuallcobley et al., Study on Specialized Intellectual Property Courts, THE INTERNATIONAL 
INTELLECTUAL PROPERTY INSTITUTE AND THE UNITED STATES PATENT AND TRADEMARK OFFICE, 1, 11-13 
(2012). 
79 Donna M. Gitter, Should the United States Designate Specialist Patent Trial Judges? An Empirical 
Analysis of H.R. 628 in Light of the English Experience and the Work of Professor Moore, 10 COLUM. SCI. 
& TECH. L. REV. 169, 193 (2009); see also, Ryan S. Goldstein at al., Specialized IP Trial Courts Around the 
World, INTELL. PROP. & TECH. L.J., 1, 3 (2006) (“[E]nforcement of IP rights can often be problematic because 
trial judges and laypeople on juries generally do not have the necessary IP law training or technical 
backgrounds to properly apply IP standards with uniformity.”). 
80 Gitter, supra note 79, at 193. 
81 Id. at 195. 
82 Zuallcobley, supra note 78, at 11-13. 
83 Id. 
84 Id. 
inconsistency of specialized courts and judges with technical backgrounds can leave parties 
with varying international decisions on the efficacy and validity of their patents. 
D. Use of a Public Forum in Litigation 
 A public forum, which is present in most court systems, has its benefits.  These 
benefits include a public result that can serve as a preventive measure against other 
competitors in future litigation disputes.85  Courts generally respect that the public has a 
right to access information on litigation materials and testimony; therefore, courts are less 
likely to allow for a blanket confidentiality designation on such matters.86  However, 
confidentiality might be a necessity for a party in a patent suit because sensitive technical 
information is frequently shared in court.87  In particular, given the ease of reverse 
engineering inventions in the pharmaceutical and biotechnology industries,88 
confidentiality is crucial in protecting the IP rights of companies in these industries. 
III. ARBITRATION AS AN ALTERNATIVE 
 As opposed to litigation, arbitration offers a dispute resolution process that reduces 
time, costs and public knowledge while providing an informed and binding decision on the 
merits.  Arbitration is a contractual agreement between parties that mutually agree to bring 
disputes before an arbitrator.89  This agreement can be made during the negotiations of a 
business contract or after a dispute has arisen.90  In a written document, the arbitration 
agreement is written in an arbitral clause.  The arbitral clause serves as a roadmap to the 
arbitration.91  Arbitral clauses may include the number of arbitrators on the panel, the scope 
of arbitration, what laws will govern, which institutional rules are applicable, where the 
                                                 
85 Michaelson, supra note 1, at 2-3. 
86 Id. 
 
87 Dimock, supra note 34. 
 
88 Schonharting, supra note 26, at 24. 
 
89 Boyd, supra note 35. 
90 Id. 
91 Id. 
arbitration will be held, and any other important components the parties find necessary to 
admit.92  In other words, arbitration can be tailored to the parties’ needs.93   
 Arbitration has been increasingly utilized as a dispute resolution process across 
industries in recent years.  This is exemplified by the number of disputes submitted to 
arbitration across ten institutions94 which shows that the caseload among these institutions 
has increased by approximately 458% between 1993 and 2011.95  To date, the World 
Intellectual Property Organization (“WIPO”) has managed approximately 450 mediation, 
arbitration, and expert determination cases.96  The majority “of these cases have been filed 
in recent years.”97  Additionally, as of June 2015, 35% of all WIPO Mediation and 
Arbitration cases involve patents.98  This trend demonstrates that arbitration is a preferred 
substitute to litigation in many cases. 
 Arbitration provides a viable alternative to litigation and indispensable benefits 
when utilized correctly.  International arbitration is more efficient and less costly than its 
litigation counterpart.99  Most international patent suits involve the risk of parallel litigation 
proceedings in multiple national courts, which can result in high costs and conflicting court 
rulings.100  International arbitration can eliminate this risk by resolving multijurisdictional 
disputes in a single proceeding.101  Unlike litigation where jurisdiction is dependent upon 
the parties’ residential status, arbitration allows for the choice of procedural and substantive 
                                                 
92 Boyd, supra note 35; see also, GARY BORN, INTERNATIONAL ARBITRATION CASES AND MATERIALS 46 (2d 
ed. 2015) (“Most modern arbitration legislation affirms the parties’ autonomy to agree upon arbitral 
procedures…”). 
93 Michaelson, supra note 1, at 3. (providing that arbitration is “a blank canvas on which parties can 
collectively create the exact process they need and no more.”). 
94 The ten institutions reviewed for their caseload between 1993 and 2011 are the American Arbitration 
Association, British Columbia International Commercial Arbitration Centre, China International Economic 
and Trade Arbitration Commission, Honk Kong International Arbitration Center, International Chamber of 
Commerce, The Japan Commercial Arbitration Association, Korean Commercial Arbitration Board, The 
Kuala Lumpur Regional Centre for Arbitration, The London Court of International Arbitration, London 
Maritime Arbitrators Association, The Arbitration Institute of Stockholm Chamber of Commerce, and 
Singapore International Arbitration Centre. 
95 Born, supra note 92, at 46. 
96 WIPO Caseload Summary, WIPO, http://www.wipo.int/amc/en/center/caseload.html. 
97 Id. 
98Joyce A. Tan, WIPO Guide on Alternative Dispute Resolution Options for Intellectual Property Offices and 
Courts, WIPO ARB. AND MEDIATION CTR., 1, 20 (2015), 
http://www.kipo.go.kr/upload/en/download/ADR_Guide.pdf. 
99 Dimock, supra note 34.  
100 Michaelson, supra note 1, at 7. 
101 Id. 
laws and the place of arbitration regardless of where the parties reside.102  While litigation 
is a one-size-fits-all model,103 arbitration is flexible and offers the opportunity for a quicker 
resolution of the dispute, lower financial burden on the parties, arbitrators who are 
specialized in the technical field at issue, confidentiality of the proceeding, avoidance of a 
jury, and international enforceability of the decision rendered. 
A. Arbitration Takes Less Time to Complete Than Its Litigation Counterpart 
 Arbitration is praised for providing a prompter resolution than litigation.104  In 
recent years, corporations have expressed concern over delays in international arbitral 
proceedings.105  Despite these concerns, a survey conducted by WIPO found that, on 
average, international arbitration proceedings take only 40% of the time required to 
complete an international litigation proceeding.106  The average arbitral proceeding lasts 
for approximately seven months.107  This quick resolution is accomplished in a number of 
ways, including subjecting the arbitrator’s pay to a potential reduction when rendering a 
decision that takes longer than the time agreed upon by both parties or through institutional 
rules which instill time limits on how long a tribunal can take to render an award.108  In the 
absence of institutional provisions or when parties choose to participate in ad hoc 
arbitration, parties can contractually agree to limit the time each party has to present its 
case before the tribunal in order to expedite the process.109  Parties may also choose to 
undergo expedited arbitration, which limits procedures and discovery in order to reach a 
more immediate resolution.110   
 Litigation also offers parties the opportunity to appeal the decisions rendered in the 
court below.  This adds a significant amount of time to the proceedings.  However, the 
decision rendered by the arbitral tribunal is final and binding on the parties neither can 
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appeal the holding.111  That is not to say that arbitration receives no judicial appellate 
review, but it is only under limited circumstances.112  Notably, arbitral institutions have 
begun including an arbitral appellate procedure to which the parties can contractually 
agree.113  Arbitral award appeals are conducted by a separate arbitral panel in a second 
tribunal.114  Overall, arbitration provides various alternatives for parties in order to resolve 
their disputes rapidly and prevent patent legal limbo. 
B. The Cost of Arbitration Is Less Than Litigation 
 Another attribute for which arbitration is highly praised is cost savings.  According 
to a survey on dispute resolution conducted by WIPO, arbitration saves, on average, 55% 
in costs compared to litigation.115  The highest cost driver in litigation is discovery; 
however, discovery in arbitration is limited and the rules are simple.116  The rules of 
evidence do not need to conform to the legal rules of the country whose law governs the 
contract, thus making the process less extensive and arduous.117  The arbitrator determines 
the necessity and validity of evidence and the parties can contractually agree to what extent 
discovery may extend.118  In other words, discovery may be as broad or as narrow as the 
parties desire.  The International Institute for Conflict Prevention and Resolution provides 
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a protocol of levels with increasing amounts of physical and electronic discovery.119  In 
using this protocol, parties can agree which level to follow during arbitration to determine 
the level of discovery.120   
 Aside from discovery, other cost drivers in litigation are futile motions, the use of 
experts,121 and jury trials.122 Futile motions can be readily avoided in arbitration because 
arbitrators have discretion in choosing whether or not to accept a motion.123  Furthermore, 
parties can limit the necessity for experts by selecting an arbitrator with a technical 
background and expertise in the field.124  Lastly, parties save costs by bypassing a jury trial.  
Oftentimes, jury trials require parties to conduct mock trials beforehand, which is costly.125  
Ultimately, arbitration provides efficient cost-saving modalities to patent disputes. 
C. Arbitrators Chosen by the Parties Can Be Specialized in the Required Technical 
Field 
 In the judicial process, parties cannot choose their judges.  However, in arbitration 
parties may choose their arbitrators.126  The arbitral tribunal generally consists of either 
one or three arbitrators.127  The parties get to choose their arbitrators based on their needs 
for the dispute at hand.128  Since patent disputes in the pharmaceutical and biotechnology 
industries often involve complex scientific and technological issues, the parties can choose 
at least one arbitrator with expertise in the field in an effort to reach a quick and cost-
effective resolution.129  For example, an arbitral tribunal can consist of an arbitrator with 
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extensive legal knowledge to assess the legal issues at hand, another arbitrator with a strong 
technical background, eliminating the need to simplify the case, and a third arbitrator with 
financial knowledge to determine the appropriate awards.130  Resolving the dispute before 
a tribunal with varying technical expertise provides the fairest opportunity for the parties 
to resolve a patent dispute quickly and cost-effectively.131 
D. Arbitral Proceedings Can Be Private and Confidential 
 Unlike litigation, which is always conducted in a public forum, arbitration is private 
unless the parties agree otherwise.132  Arbitrators are inherently sworn to secrecy about the 
proceedings of an arbitration, while parties are not.133  Even though parties are not per se 
sworn to secrecy, they may contractually agree to a confidentiality provision in their 
arbitral clause or agree to one post dispute.134  The privacy of arbitral proceedings is 
particularly important in patent disputes, which oftentimes involve sensitive technical 
information.135  Another benefit of a confidentiality provision is that privacy allows the 
disputes to be resolved without attention from media and competitors.136  A byproduct is 
the increased likelihood of preserving the commercial relationship between the parties.137  
Such a relationship is less strained in a private setting where the interactions can be 
informal and where outside commentary and ridicule are eliminated.138  Furthermore, 
commercial relationships with third-party companies are not impacted by exposing 
sensitive financial information, terms and conditions, royalty rates, and more.139   
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E. Arbitration Does Not Require a Jury 
 In the past five years, juries have decided 75% of the damage awards in patent 
litigation in the U.S.140  Median awards decided by juries have been sixteen times greater 
than median bench trial awards.141  This discrepancy occurs because jury members are not 
required to have any specific technical expertise.142  Their lack of knowledge on the subject 
matter obligates parties to obtain experts in the field in order to simplify the patent or 
issue.143  Oversimplification runs the risk that juries fail to fully appreciate the details of 
the patent dispute, potentially leading to improper and unreasonable decisions.144  
Additionally, jury members are traditionally swayed by factors other than providing 
justice.145  For example, jury members may have a personal bias or empathy for the party 
whom they view as the “little guy.”146  Lastly, juries are not required to explain their 
decisions.147  Alternatively, parties in an arbitration may contractually agree that the 
arbitral award include a document explaining the tribunal’s reasoning for rendering such 
an award.148  Therefore, arbitration can help reduce bias, prevent oversimplification, and 
provide for a logical and well-reasoned award.149   
F. Arbitral Rulings Have a Greater Chance of International Enforceability 
 International arbitration awards are enforceable in most countries around the 
world.150  The international treaty known as the New York Convention,151 ratified in 1959, 
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has been adopted by 156 member states.152  The Convention requires that all member states 
enforce arbitration agreements between parties and recognize arbitral awards that were 
decided in other member states.153  Even though the New York Convention creates a global 
arbitral award enforcement system, however, not all countries recognize arbitral awards on 
patent validity and infringement disputes.154  In other words, even if two parties 
contractually agree to arbitrate such disputes, enforcement of the award will not be 
recognized in those countries.  For example, French courts will not enforce an arbitral 
decision on the patent validity of a French patent but will recognize a decision on civil 
action for infringement.155  Germany also holds that patent validity disputes are not 
arbitrable and therefore unenforceable by German courts.156  However, countries such as 
the U.S. and Australia will recognize arbitral rulings on patent validity.157  Finally, courts 
within countries such as Japan are unclear as to whether an arbitral decision on civil patent 
infringement and validity matters will be enforced.158  Therefore, forum shopping is an 
important aspect of patent arbitration and the parties must be aware of the rules of each 
country before contractually agreeing to arbitration. 
IV. UTILIZING ARBITRATION TO RESOLVE PATENT DISPUTES 
 Patent arbitration is a strong and viable alternative to patent litigation in resolving 
patent disputes in the pharmaceutical and biotechnology industries.  However, while most 
patent disputes arising within these two industries are arbitrable, patent validity is not a 
recommended subject matter to be submitted to international arbitration due to the 
disagreements among countries as to whether arbitral holdings on patent validity should be 
enforced. 159  Parties should only arbitrate issues of patent validity when the parties are 
located within countries that support party autonomy to arbitrate any legal issue they 
choose.160  However, for claims involving, inter alia, infringement, licensee/licensor 
agreements, and breach of contract, arbitration will save time and reduce costs, thereby 
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promising a greater return on R&D and protection of a patent during its limited monopoly 
term.161  Arbitration will also protect the companies in the pharmaceutical and 
biotechnology industries from public scrutiny while preserving their commercial 
relationships, license agreements, and sensitive technical information.162  However, the 
efficiencies of arbitration only go as far as the parties’ contractual agreement.163  Since 
arbitration is a blank canvas on which the parties have complete autonomy to modify 
procedures to best fit their needs, the parties ought to avoid creating a patent arbitration 
agreement that closely resembles litigation’s discovery process, judicial review, motions, 
and open-ended time limit.164  
 When the parties collectively agree to write an arbitral clause that allows arbitration 
to resemble litigation, they are inheriting the deficiencies of litigation.165  The process-
enhancing techniques of arbitration are often not fully recognized as a result of the parties’ 
and counsels’ inexperience with arbitration, counsels’ career experiences in primarily 
litigation or litigation-like proceedings, and counsels’ and parties’ previous prejudice to 
arbitration.166  The College of Commercial Arbitrators created the Protocols for 
Expeditious, Cost-Effective Commercial Arbitration in order to aid counsel in creating a 
beneficial arbitral process.167  The protocols suggest, among other things, that counsel and 
parties proactively limit discovery to the essential documents,168 avoid judicial review,169 
limit motions,170 and set time limits on arbitration.171  Therefore, it is a fundamental 
requirement for counsel to learn how to prepare appropriate arbitral clauses.   
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A. Writing the Arbitral Clause 
 Counsel in the pharmaceutical and biotechnology industries must have a concrete 
understanding on how to prepare arbitral clauses that benefit their clients in patent disputes.  
The arbitral clause in a contract between two parties governs the entire arbitral 
proceeding.172  The way in which the clause is written is crucial to the success of the arbitral 
proceeding.  There are eight commonly used elements in arbitration agreements: “(a) the 
agreement to arbitrate; (b) the scope of the disputes submitted to arbitration; (c) the use of 
an arbitral institution and its rules; (d) the seat of the arbitration; (e) the method of 
appointment, number and qualifications of arbitrators; (f) the language of the arbitration; 
and (g) a choice-of-law clause.”173  While parties may add more elements to their 
agreements, the original eight should be present in order to avoid ambiguity and increase 
the likelihood of enforcement of the arbitral agreement.174   
 Many institutions have model arbitral clauses to guide counsel and parties in their 
preparation.175  For example, WIPO has an alternative dispute resolution sector that 
provides the following arbitral clause template: 
Any dispute, controversy or claim arising under, out of or relating to this 
contract and any subsequent amendments of this contract, including, 
without limitation, its formation, validity, binding effect, interpretation, 
performance, breach or termination, as well as non-contractual claims, shall 
be referred to and finally determined by arbitration in accordance with the 
WIPO Arbitration Rules.  The arbitral tribunal shall consist of [a sole 
arbitrator][three arbitrators].  The place of arbitration shall be [specify 
place].  The language to be used in the arbitral proceedings shall be [specify 
language].  The dispute, controversy or claim shall be decided in accordance 
with the law of [specify jurisdiction].176 
While the WIPO model arbitral clause provides a beneficial starting point, there are various 
ways to increase its efficacy for patent disputes.   
1. Recommendations for Arbitral Clauses 
 In order to increase the efficiency of arbitration during patent disputes for 
companies in the pharmaceutical and biotechnology industries, counsel should be aware of 
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the following potential modifications to the arbitration agreement.  Arbitral proceedings 
are tailored to the unique relationships and circumstances of the parties thereby making it 
impossible to create a series of recommendations that would be beneficial in all situations.  
However, the following three recommendations should always be considered when 
drafting arbitral clauses. 
 First, parties should limit the scope of the arbitration agreement.  The scope of the 
arbitration agreement governs the jurisdiction of the arbitral tribunal over the dispute.177  
Generally, the scope of international arbitration clauses are construed broadly in order to 
prevent the extra expense of parallel proceedings.178  However, in cases where arbitral 
clauses revolve around patent disputes, the scope of the submitted disputes should be 
drafted narrowly.  As discussed above, rulings on patent validity may not be enforceable 
in certain countries and a narrowly defined scope helps prevent the tribunal from ruling on 
issues of patent validity.  Avoidance of patent validity issues is particularly important when 
one or both parties is a resident of a country that either does not enforce arbitral decisions 
on patent validity or is ambiguous on the matter of enforcement.  However, removing 
patent validity from the scope when both parties are residents of countries that recognize 
arbitration decisions on patent validity can also be beneficial.179  In the U.S. for example, 
validity decisions must be submitted to the patent office, thus rendering them public 
documents180 thereby eliminating one of the key benefits of arbitration – confidentiality.181  
Another alternative for parties is to keep the scope of the agreement broad, but parties can 
then limit the tribunal’s decision to whether or not royalties are due.182  This also effectively 
eliminates the chances of the tribunal ruling on validity.183 
 Second, both parties should agree to an appellate arbitral review.  Unless the parties 
agree to do so, an appeal is not available.184  Appellate arbitral reviews can play an 
important role because of the complexity of patents in the pharmaceutical and 
biotechnology industries and the opportunity for large damage awards.  In fact, these 
industries have the highest median damages awards rendered in litigation.185  Courts have 
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a limited ability to vacate or annul arbitral awards;186 therefore, companies within these 
industries would find it beneficial to establish a secondary tribunal to review the arbitral 
award and modify it if necessary.187  This method safeguards companies from having to 
pay unreasonably large sums in damages. 
 Lastly, because the details of a patent are sensitive, especially in industries where 
reverse engineering is a threat to products, parties should include a confidentiality 
agreement.  This agreement will bind the parties to secrecy and prevent them from leaking 
to the public important information on finances, patent technology, the proceedings, and 
more.188  Confidentiality agreements can be signed post dispute but it is best for the parties 
to mutually agree to secrecy before a dispute arises in order to ensure neither party releases 
confidential information prior to signing such an agreement. 
2. Sample Arbitral Agreement 
 This sample arbitral agreement was created through the aid of WIPO’s model 
arbitration clause, the International Bar Association’s Guidelines for Drafting International 
Arbitration Clauses, and the American Health Lawyers Association’s (“AHCA”) Guide to 
Arbitration Clauses.  Importantly, whenever parties create an arbitral clause, the initial 
clause should follow the template of the institution through which the parties choose to 
arbitrate, if they choose to arbitrate through an institution at all.189  In the following 
example, the first paragraph is a clause which does not follow any institutional template. 
 All [disputes][controversies][claims] arising out of or in connection 
with this contract, including any questions regarding its formation, validity, 
binding effect, interpretation, performance, breach or termination, as well 
as non-contractual claims, shall be referred to and finally determined by 
arbitration in accordance with [institutional rules].  The following matters 
are specifically excluded from arbitration hereunder: questions regarding 
patent validity. 
 The arbitral tribunal shall consist of three arbitrators, one selected 
by the claimant in the request for arbitration, the second selected by the 
respondent within [time] of receipt of the request for arbitration, and the 
third selected by the claimant and the respondent within [time] of the 
selection of the second arbitrator.  If any arbitrators are not selected within 
these time periods, [the designated institution] shall, upon the request of any 
party, make the selection(s).   
 The place of arbitration shall be [place].  The language to be used in 
the arbitral proceedings shall be [language].  The 
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[dispute][controversy][claim] shall be decided in accordance with the law 
of [jurisdiction]. The procedure to be followed during arbitration shall be 
agreed by the parties within [time] or, failing such agreement, determined 
by the arbitral tribunal after consultation with the parties within [time]. 
 Within [time] after an award is issued on the 
[dispute][controversy][claim], a party may file an appeal with a second 
arbitral tribunal.  Within [time] after such an appeal is filed, any other party 
may file a response or a cross appeal.  Once an appeal is filed, no party will 
pursue an action in court to vacate, modify or enforce the award.  The 
tribunal shall consist of [one arbitrator selected by the claimant and the 
respondent within [time] after filing of the appeal][three arbitrators, one 
selected by the claimant in the request for appeal, the second selected by the 
respondent within [time] of receipt of the request for appeal, and the third 
selected by the claimant and the respondent within [time] of the selection of 
the second arbitrator].  The review shall be in accordance with the 
[institutional rules chosen above].  The place of appellate arbitration shall 
be [place].  The language to be used in the arbitral proceedings shall be 
[language].  The [dispute][controversy][claim] shall be decided in 
accordance with the law of [jurisdiction]. 
 The existence and content of the arbitral proceedings and any 
rulings, awards, testimonies or materials shall be kept confidential by the 
parties and members of the arbitral tribunal except (i) to the extent that 
disclosure may be required of a party to fulfil a legal duty, protect or pursue 
a legal right, or enforce or challenge an award in bona fide legal proceedings 
before a judicial authority, (ii) with the consent of all parties, (iii) where 
needed for the preparation or presentation of a claim or defense in 
arbitration, (iv) where such information is already in the public domain 
other than as a result of a breach of this clause, or (v) by order of the arbitral 
tribunal upon application of a party.190 
 
 This sample arbitral agreement is beneficial for parties dealing with a patent dispute 
because it contains the suggested modifications of a limited scope by requiring issues of 
patent validity to not be submitted to arbitration, an agreement for an appellate arbitral 
review, and a confidentiality provision.  It also suggests the use of a three party tribunal for 
the initial arbitral review given the typically technical and complex nature of patented 
inventions in the pharmaceutical and biotechnology industries.  Lastly, the clauses specify 
time constraints on the parties and the tribunal in order  to aid in the reduction of time spent 
disputing a conflict and costs.  As with all arbitral agreements, parties should work 
diligently to tailor the agreement to their specific needs and relationship despite the 
constraints and recommendations found within any template. 
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V.  CONCLUSION 
 International arbitration is an underutilized method of patent dispute resolution.  
However, the biotechnology and pharmaceutical industries are well suited for patent 
arbitration and would benefit from implementing this alternative form of international 
dispute resolution in place of international litigation.  Pharmaceutical and biotechnology 
companies should seize the opportunity to arbitrate patent disputes to save time and costs, 
protect trade secrets and commercial relationships, and avoid unreasonable jury awards.  
Litigation is a one-size-fits-all process that, even in the face of particular benefits, is 
ultimately an arduous, expensive, and inefficient process that has the potential to harm 
parties seeking to enforce their patent rights.  By contrast, arbitration can provide the same 
benefits as litigation more quickly and at considerably less cost while preserving flexibility 
and confidentiality.  If parties and counsel take the time to learn how to create arbitration 
agreements that fit their needs while avoiding a litigation-like process, they will begin to 
recognize the returns of international arbitration that companies in the commercial realm 
have reaped for years.  By following the recommendations in this article, companies within 
the pharmaceutical and biotechnology industries will effectively protect their patent rights 
internationally while avoiding the complexities and inconsistencies of international 
litigation.  International patent arbitration has the potential to be a viable future for dispute 
resolution in these two universally important and indispensable industries. 
